Etilevodopa is an ethyl-ester prodrug of Levodopa which is used for the treatment of Parkinson's disease (PD). It is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Levodopa is the direct precursor of dopamine.

Etilevodopa passes unchanged through the stomach to the duodenum and is subsequently absorbed into the bloodstream as Levodopa [1]. Etilevodopa has a greater solubility in the stomach, faster passage to the small intestine, and a shortened time to maximum Levodopa concentration, compared with standard Levodopa [2].

37178-37-3

C11H15NO4

225.24

L-DOPA ethyl ester;Levodopa ethyl ester

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years